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Background. Little is known about temporal trends in frequencies of clinically relevant ARV resistance mutations in HIV strains
from U.S. patients undergoing genotypic testing (GT) in routine HIV care. Methods. We analyzed cumulative frequency of HIV
resistance among patients in the HIV Outpatient Study (HOPS) who, during 1999–2008 and while prescribed antiretrovirals,
underwent GT with plasma HIV RNA >1,000 copies/mL. Exposure ≥4 months to each of three major antiretroviral classes
(NRTI, NNRTI and PI) was deﬁned as triple-class exposure (TCE). Results. 906 patients contributed 1,570 GT results. The annual
frequency of any major resistance mutations decreased during 1999–2008 (88% to 79%, P = 0.05). Resistance to PIs decreased
among PI-exposed patients (71% to 46%, P = 0.010) as exposure to ritonavir-boosted PIs increased (6% to 81%, P<0.001). Non-
signiﬁcant declines were observed in resistance to NRTIs among NRTI-exposed (82% to 67%), and triple-class-resistance among
TCEpatients(66%to41%),butnottoNNRTIsamongNNRTI-exposed.Conclusions.HIVresistancewascommonbutdeclinedin
HIV isolates from subgroups of ARV-experienced HOPS patients during 1999–2008. Resistance to PIs among PI-exposed patients
decreased, possibly due to increased representation of patients whose only PI exposures were to boosted PIs.
1.Introduction
Highly active combination antiretroviral therapy (cART)
has signiﬁcantly improved survival and reduced the rates
of AIDS-related complications among HIV-infected persons
[1–3].EmergenceofHIVvariantswithreducedsusceptibility
to antiretroviral (ARV) medications can signiﬁcantly limit
the eﬀectiveness and durability of treatment [3–8]. Use of
ARV resistance testing to optimize cART selection has been
associated with better virologic and clinical outcomes [9–
11] and improved survival [12], and resistance testing is
now generally recommended in the clinical management
of HIV infection [13–15]. We have previously shown that
use of genotypic and phenotypic testing increased in the
HIV Outpatient Study (HOPS) during 1999–2006 and that
the likelihood of testing varied by HIV disease severity and
demographic characteristics [16].
Recent European and Canadian studies have suggested
that both the prevalence [17, 18] and incidence [19, 20]o f
ARV resistance among HIV-infected persons have declined,
duepredominatelytoadecreaseintheproportionofpatients
with pre-cART mono- or dual-ARV experience, and the
increasing use and eﬀectiveness of more tolerable and potent
cART regimens that appear less likely to result in resistance2 AIDS Research and Treatment
mutations [18–22]. However, relatively few recent data on
prevalence or incidence of ARV resistance mutations are
available from US patient populations [7, 23–25]. We sought
to assess frequencies and trends in ARV resistance among
HIV strains isolated from a demographically diverse cohort
of ARV-experienced US patients who underwent genotypic
testing (GT) as part of routine care between 1999 and 2008.
2. Methods
2.1. The HIV Outpatient Study. The HIV Outpatient Study
(HOPS) is an ongoing, longitudinal cohort study of HIV-
infected patients in care followed at HIV specialty clinics
in the US since 1993. The HOPS methodology has been
described previously [26]. In brief, trained staﬀ abstract
patient data, including sociodemographic characteristics,
diagnoses, treatments, and laboratory values (including
results of antiretroviral resistance testing), from medical
records and enter them into an electronic database for
central processing and analysis. HIV drug resistance testing
is performed at the discretion of the clinician provider.
The institutional research review boards of the Centers
for Disease Control and the local participating sites have
approved and reviewed the ethical conduct of this study
yearly.
2.2. Study Population. For this analysis, we examined data
from active participants seen at 10 HOPS clinics between
January 1, 1999, and December 31, 2008, using the HOPS
dataset as of September 30, 2009. Participants were consid-
ered active if they had at least two HOPS-related encounters
documented (i.e., clinic visits, hospitalizations, and labora-
tory measurements but not telephone calls), and at least
one of these encounters occurred during the calendar years
of interest. The study population was restricted to patients
who underwent GT while receiving ARV therapy with a
documented plasma HIV RNA viral load >1,000copies/mL;
we chose the measurement most proximal to the date of GT
within the six months prior and two weeks after the GT
during 1999–2008. Only GT results documented on or after
the ﬁrst HOPS visit were considered; GT results indicating
insuﬃcient virus or inadequate specimen were excluded
from the analyses.
2.3. Variable Deﬁnitions. “Mono-dual NRTI exposure” was
deﬁned as any prior treatment with a regimen containing
only one or two NRTIs as of the last eligible genotypic test
in the year of interest. “Triple-class exposure” (TCE) was
deﬁned as four continuous months of exposure to ARVs
fromeachofthethreemainclasses(i.e.,NRTIs,NNRTIs,and
PIs)asofthelasteligiblegenotypictestintheyearofinterest;
resistance to other novel drug classes was not evaluated.
“Only cART exposure” was deﬁned as having never been
prescribed non-cART (i.e., mono-dual NRTI) regimens as
of the last eligible genotypic test in the year of interest.
“Triple-class resistance” (TCR) was deﬁned as the presence
or presumed accumulation (i.e., any prior documentation)
of mutations to ARVs from each of the three main classes.
2.4. Analysis Methods. Using the International AIDS Society
(IAS) December 2008 listing of clinically relevant mutations,
we assessed the frequency of major HIV resistance mutations
in viruses isolated from patients who were followed in
HOPS during 1999–2008 and underwent at least one eligible
genotype test during that period. For patients who had
multiple genotypic tests per year, we focused on the last
test. Annual frequencies of ARV resistance were calculated
as the number of patients with genotype(s) that during a
calendar year demonstrated resistance, or had previously
demonstrated resistance (numerator), divided by the num-
ber of patients with an eligible genotype performed in that
year (denominator) and expressed as a percentage. Thus,
resistance was determined by the presence of either a current
or previously detected mutation(s) among patients tested
that year, even if a previously detected mutation(s) was
no longer apparent on the most recent resistance assay.
We examined resistance to each of the three main drug
classes (NRTIs, NNRTIs, and PIs) among all ARV-treated
patients and among patients known to have been speciﬁcally
exposed to agents in these drug classes. We also examined
the frequency of TCR among TCE patients. Because M184V
is a frequently observed mutation that develops rapidly after
exposure to lamivudine and emtricitabine, but which does
not confer resistance to all NRTIs, we conducted alternate
analyses excluding this mutation. Finally, we assessed the
likely impact of excluding genotypic tests performed at
HIV RNA viral load ≤1,000copies/mL on our ﬁndings, by
examiningfrequencyofinsuﬃcientspecimensandresistance
patterns in this subset.
Resistance was assessed as of the last eligible genotypic
test in the year of interest. Trends in patient characteristics
and in mutation frequency were evaluated using general
linear models (PROC GLM), reporting P values over the 10-
year period of the study. All analyses were performed using
SAS version 9.1 (Cary, NC). Statistical associations with P
values <0.05 were considered signiﬁcant.
3. Results
3.1. Temporal Trends in Genotypic Resistance Testing. The
6,158 HOPS patients under observation during 1999–2008
had a total of 3,305 GT results during this period. We
identiﬁed 1,867 (56%) genotypic tests performed while
the patients were prescribed ARVs, of which 1,570 (84%)
were performed when the most proximal HIV RNA was
>1,000copies/mL. These 1,570 GT results were obtained
from a total of 906 patients, of whom 541 patients con-
tributed one eligible GT result, 206 contributed two results,
and 159 contributed ≥3 results. Taking the last GT result per
patient per year resulted in 1,436 GT assessments for 906
unique patients being available for resistance trend analyses
during 1999–2008.
Notably, while the annual number of active HOPS
participants receiving ARVs in the HOPS oscillated around
2,700 during 1999–2008, the annual number and relative
proportion of participants receiving ARVs who had at least
one documented episode of viremia (HIV RNA >1,000
copies/mL) decreased markedly from nearly 1,400 to fewerAIDS Research and Treatment 3
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Figure 1: Number of patients who underwent genotypic testing
(GT) while prescribed antiretrovirals (ARVs) and viremic (HIV
viral load >1,000copies/mL), the HIV Outpatient Study, 1999–
2008.
than 500 participants (P<0.0001, Figure 1). Correspond-
ingly, since 2003, the number of persons who were eligible
for GT and met inclusion criteria for our analyses decreased
steadily (from 240 persons in 2003 to 63 persons in 2008,
P<0.0001). Furthermore, the percentage of genotypic tests
performed among ARV-treated patients whose HIV RNA
was ≤1,000copies/mL (i.e., genotypic tests that we excluded
from the present analyses) increased over time (4.5% in
1999 (6/133) versus 18.2% (16/88) in 2008, P = 0.008).
SeeSection 3.5forsupplementalresultsforexcludedpatients
with HIV RNA ≤1,000 copies/mL.
3.2. Characteristics of Patients with Genotypic Tests Performed.
Of the 906 patients analyzed, the median age was 43 years,
77% were male, 37% were non-Hispanic black, 14% were
Hispanic or other or unknown race/ethnicity, 54% were
men who had sex with men (MSM), 11% were injection
drug users at the time of HIV diagnosis, and 29% were
heterosexuals (Table 1). As of their last eligible genotypic
test, 49% had public insurance, 38% had a CD4+ cell
count<200 cells/mm3, 80% had been diagnosed with AIDS
by immunologic or clinical criteria, and the median HIV
RNA was 4.3log10 copies/mL at last eligible genotypic test.
In crude analyses, the patients who underwent GT during
1999–2008 were increasingly more likely over time (test for
trend, P<0.05) to be older, female, of non-Hispanic black
race/ethnicity, to have reported heterosexual risk for HIV
infection, and to have been publicly insured (Table 1). The
median CD4+ cell count appeared higher, and the HIV viral
load appeared lower among patients who underwent GT in
the middle of the study period (i.e., year 2004) compared
with the start and the end of the period, without statistically
signiﬁcant trends over time (Table 1).
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Figure 2: Frequency of antiretroviral exposures, according to ARV
class, among viremic (HIV viral load >1,000copies/mL) patients
who underwent genotypic testing in the HIV Outpatient Study,
1999–2008. Note: Any “PI exposed” included ritonavir-boosted
and unboosted regimens. “PIB exposed” included only ritonavir-
boosted regimens.
3.3. Temporal Trends in ARV Exposures. From 1999 to 2008,
among patients who underwent GT each year, the annual
percentage of patients with prior NNRTI exposure increased
(66% to 75%, test for linear trend, P = 0.012), while the
percentage with any prior PI exposure remained stable (89%
to 87%, P = 0.89) and the percentage with ritonavir-boosted
PI exposure increased markedly (6% to 81%, P<0.001)
(Figure 2). The annual percentages with mono-dual NRTI
exposure decreased (75% to 52%, P<0.001), while the
fraction of cART-only exposed participants increased (19%
to38%,P<0.001),andthefractionofparticipantswithTCE
remained unchanged (47% to 51%, P = 0.11) (Figure 3).
3.4. Temporal Trends in Frequency of Genotypic Resistance.
During 1999 to 2008, the annual frequency of any resistance
mutations decreased for all patients tested (88% to 79%, test
for linear trend P = 0.054) and for persons with mono-
dual NRTI exposure (93% to 88%, P = 0.066) but not
among persons who were exposed only to cART (68% to
63%,P = 0.32)orwhohadTCE(95%versus94%,P = 0.43)
(Table 2, part A). Although the diﬀerences were not statically
signiﬁcant, as evidenced by overlapping 95% CIs, the
annual frequencies of resistance tended to be lower, among
cART-only exposed patients compared with mono- and
dual-NRTI-exposed patients or patients with TCE (Table 2,
part A).
Among all patients receiving genotypic tests, regardless
of their ARV regimen exposures, the frequency of any major
resistance mutations (88% to 79%) (Table 2, part A top line)
as well as NRTI mutations (82% to 67%) and PI mutations
(65% to 41%) tended to decrease over time, but only the4 AIDS Research and Treatment
Table 1: Characteristics of ARV-experienced patients who had genotypic testing performed at viral load >1000 copies/mL and while on
ARVs in selected calendar years, and overall, the HIV Outpatient Study, 1999–2008.
1999 2004 2008 Unique total§
N % N % N % N %
Had GT in this yr → 118 164 63 906
Age, years∗†
Median (IQR) 40 (36, 47) 43 (39, 48) 41 (38, 51) 43 (38, 49)
<35 18 15.2 17 10.4 9 14.3 110 12.1
35–49 78 66.1 110 67.1 36 57.1 583 64.4
50+ 22 18.6 37 22.6 18 28.6 213 23.5
Gender†
Female 25 21.2 36 22.0 24 38.1 208 23.0
Male 93 78.8 128 78.0 39 61.9 698 77.0
Race†
White 73 61.9 75 45.7 22 34.9 448 49.4
Black 30 25.4 65 39.6 30 47.6 334 36.9
Other/unknown 15 12.7 24 14.6 11 17.5 124 13.7
HIVRisk†
Heterosexual 31 26.3 53 32.3 27 42.9 266 29.4
IDU 12 10.2 15 9.1 9 14.3 102 11.3
MSM 70 59.3 85 51.8 23 36.5 487 53.8
Other/unknown 5 4.2 11 6.7 4 6.4 51 5.6
Insurance∗†
Private 54 45.8 58 35.4 21 33.3 381 42.0
Public 49 41.5 93 56.7 37 58.7 444 49.0
Other/unknown 15 12.7 13 7.9 5 7.9 81 8.9
CD4+ count, cells/mm3∗
Median (IQR) 225.5 (105, 360) 272 (163, 432) 170 (64, 325) 267.5 (124, 433)
<200 54 45.8 56 34.2 36 57.1 347 38.3
200–349 32 27.1 46 28.0 11 17.5 229 25.3
350–499 16 13.6 34 20.7 7 11.1 162 17.9
500+ 15 12.7 26 15.8 8 12.7 150 16.6
Missing 1 0.8 2 1.2 1 1.6 18 2.0
Nadir CD4+ count, cells/mm3∗†
Median (IQR) 99 (34, 213) 126 (40, 247) 55 (20, 206) 105 (32, 247)
<50 38 32.2 52 31.1 29 46.0 278 30.7
50–199 44 37.3 52 31.7 18 28.6 306 33.8
200–349 24 20.3 38 23.2 12 19.0 184 20.3
350+ 9 7.6 20 12.3 4 6.4 101 11.2
Missing 3 2.5 3 1.8 0 0.0 37 4.1
HIV RNA viral load, copies/mL∗
Median log (IQR) 4.6 (3.9, 5.0) 4.2 (3.6, 4.8) 4.5 (3.7, 5.0) 4.3 (3.6, 4.9)
1,000–9,999 35 29.7 65 39.6 23 36.5 368 40.6
10,000–99,999 54 45.8 69 42.1 23 36.5 363 40.1
≥100,000 29 24.6 30 18.3 17 27.0 175 19.3
AIDS∗ 99 83.9 133 81.1 52 82.5 728 80.4
Antiretroviral exposure∗
3TC/FTC exposed 110 93.2 158 96.3 62 98.4 856 94.5
NRTI exposed 118 100.0 164 100.0 63 100.0 905 99.9
NNRTI exposed 78 66.1 128 78.1 47 74.6 656 72.4AIDS Research and Treatment 5
Table 1: Continued.
1999 2004 2008 Unique total§
N % N % N % N %
Had GT in this yr → 118 164 63 906
PI exposed (any) 105 89.0 144 87.8 55 87.3 799 88.2
Ritonavir-boosted PI exposed 7 5.9 109 66.5 51 81.0 478 52.8
Mono-dual NRTI exposed 88 74.6 99 60.4 33 52.4 515 56.8
Triple-class exposed (TCE) 55 46.6 94 57.3 32 50.8 496 54.8
Only cART exposed 22 18.6 54 32.9 24 38.1 299 33.0
Anyexposure to all 3 classes of
agents(NRTI, NNRTI, and
PI)
71 60.2 109 66.5 39 61.9 566 62.5
ARV exposure duration among
those exposed with complete
and evaluable ARV history,
median months∗
n Median n Median n Median n Median
3TC/FTC exposed 110 22 158 43 62 58 856 37
NRTI exposed 118 44 164 71 63 73 905 62
NNRTI exposed 78 12 128 19 47 23 656 20
PI exposed (any) 105 28 144 51 55 56 799 43
Ritonoavir-boosted PI
exposed 7 5 108 23 51 36 477 21
Mono-dual NRTI exposed 88 19 98 12 31 7 503 13
Triple-class exposed (TCE) 38 11 75 46 29 57 394 38
Only cART exposed 11 15 54 36 24 39 299 34
Number of ARVs exposed to
date, median 118 6 164 8 63 7 906 7
Duration of ARV exposure,
years, median 118 4.0 164 6.2 63 6.2 906 5.3
§Total number of unique patients during 1999–2008.
∗As of last eligible genotypic test in the year. (For clinical measurements, only values within 6 months prior through 2 weeks after the ﬁrst eligible genotypic
test were considered, the closest one chosen to characterize the patient at time of the GT.).
†P value for trend during 1999–2008 was <0.05.
IQR: interquartile range. GT: genotypic testing; cART: combination antiretroviral therapy; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-
nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; TCE: triple-class exposed; MSM: men who have sex with men; IDU: injection drug use.
decline in PI resistance was statistically signiﬁcant (Table 2,
part B). The resistance ﬁndings were observed in the context
of an increasing duration of cumulative months of exposure
to all major classes of ARVs among the patients we studied
(Table 1).
Inanalysesrestrictedtosubsetsofpatientsexposedtothe
relevant ARV drug classes, the frequencies of resistance to
NRTIs (82% to 67%, test for linear trend P = 0.094) among
NRTI-exposed patients and to NNRTIs (71% to 68%, P =
0.38) among NNRTI-exposed did not decrease signiﬁcantly,
but the frequency of resistance to PIs (71% to 46%, P =
0.010) among PI-exposed did (Table 2,p a r tC ;Figure 4).
The annual frequency of TCR among patients with TCE also
did not decrease signiﬁcantly (66% to 41%, P = 0.094)
(Figure 4).
In the sensitivity analyses that excluded the M184V
mutation in reverse transcriptase, the frequency of NRTI
resistance was 10–15% lower in each given calendar year, but
the frequency of TCR decreased by <5% in each year (data
not shown). Furthermore, when we restricted analyses to the
ﬁrst or the last genotypic test per patient during 1999–2008,
to avoid correlated outcomes in the analyses, the declines in
resistance observed in the primary analyses persisted.
The decrease in prevalence of PI resistance, both within
the entire cohort and among persons exposed to PIs,
correlated with a shift in exposures to speciﬁc PIs. The most
common current or prior PI exposures in 1999 were to nel-
ﬁnavir (70%), indinavir (69%), saquinavir (66%), and full-
dose ritonavir (51%), whereas by 2008, the most common PI
exposures were to low-dose ritonavir for PI boosting (75%),
lopinavir (65%), atazanavir (53%), and indinavir (40%).
Furthermore, we did not see a trend whereby exposure to
PIs (as a class) was increasingly distanced from the date
of genotype (i.e., diﬀerential risk for reversion to wild-type
virus). In each calendar year, among patients who had any
PI exposure to date, over 75% underwent GT while being
prescribed at least one PI agent.
3.5. ARV Resistance according to HIV RNA Level. In sup-
plemental analyses, we compared the frequency (non-
cumulative)ofresistancemutationsdetectedineachpatient’s6 AIDS Research and Treatment
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Figure 3: Frequency of ART experience categories, among viremic
(HIV viral load >1,000copies/mL) patients who underwent geno-
typic testing in the HIV Outpatient Study, 1999–2008.
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Figure 4: Frequency of genotypic resistance by class of antiretro-
viral, among exposed patients, in the HIV Outpatient Study, 1999–
2008.
most recent viral isolate from 2004–2008, according to HIV
RNA level at GT, contrasting results for patients whom
we included (HIV RNA >1,000copies/mL) and excluded
(HIV RNA ≤1,000copies/mL) in our primary analyses.
Of 624 unique patients who had their last GT while on
ARVs in that period, 42 (7%), and 143 (23%) patients,
respectively, had GT performed with the closest HIV RNA
in the range of 500–1,000 copies/mL and <500 copies/mL.
The percentages of patients missing GT results because of
“insuﬃcient specimen” were 2%, 12%, and 46% in samples
with HIV RNA >1,000copies/mL, 500–1,000 copies/mL,
and<500 copies/mL, respectively. In the remaining evaluable
isolates, the frequency of any major IAS resistance mutation
was 76%, 76%, and 47% for the three HIV RNA strata,
respectively.
4. Discussion
As treatment options for HIV-infected patients have
improved over time in terms of greater eﬀectiveness, tol-
erability, and sheer number of available antiretrovirals, we
found that a decreasing proportion of ARV-treated patients
in our diverse US-based cohort had viremia and thus were
candidates for GT to optimize cART (Figure 1). Among
ARV-experienced patients in our cohort who underwent GT
in the context of routine outpatient HIV care during 1999–
2008, viruses harboring resistance mutations to the main
ARV classes were detected with either a constant or possibly
decreasing frequency over time; resistance mutations to
protease inhibitors decreased signiﬁcantly in viral strains of
patients who had ever been exposed to PIs.
The magnitude and temporal trends in the frequency
of resistance mutations among HIV strains isolated from
patients who undergo GT can be inﬂuenced by a myriad of
factors, including but not necessarily limited to (i) changes
in the sociodemographic and clinical characteristics of the
patient population over time, particularly in a dynamic
cohort such as the HOPS in which patients can enter or leave
care; (ii) changes in the nature and extent of ARV exposure
over time (e.g., decreasing exposure to mono- or dual-NRTI
regimens, increasing exposure to newer more potent and
tolerable cART regimens as ﬁrst-line or salvage therapy);
(iii) more widespread utilization of GT and changes in the
characteristics of patients considered appropriate candidates
for such testing; (iv) archiving of mutations in the absence
of selective antiretroviral drug pressures; (v) cohort-level
changes in the degree of patient adherence to prescribed
ARVs and the related likelihood of experiencing viremia
while prescribed cART.
It is important to note that our ﬁndings regarding the
extent of and trends in the frequency of ARV resistance
mutations apply only to the decreasing annual proportion
of HOPS patients eligible for resistance testing [16], that
is, persons who experienced viremia while receiving cART.
Our aim was to describe what clinicians may see in
practice when testing ARV-experienced patients. Modeling
of population-wide prevalence of resistance in the HOPS
cohort (including both viremic and virologically suppressed
patients on cART), which was not undertaken here but
has been attempted in other populations [25, 27], would
presumablyreveallowerprevalenceofresistancecohort-wide
and potentially diﬀerent trends over time. Such modeling
approaches typically require strong assumptions about the
likelihood of archived resistance mutations among patients
who are currently virologically suppressed and imputations
of missing data for many ARV-experienced patients who did
not undergo GT (the bulk of ARV-experienced patients in
the HOPS, per Figure 1) but can provide useful comparative
data in large samples under diﬀerent assumed scenarios.AIDS Research and Treatment 7
Table 2: Frequency of resistance mutations among ARV-experienced patients who had genotypic testing performed at viral load
>1,000copies/mL and while on ARVs, by year, the HIV Outpatient Study, 1999–2008.
Patient subgroup 1999 2004 2008 P trend∗
%[ N]% [ N]% [ N]
Part A. Frequency of any resistance among all tested in the year—by patient subgroup
All patients tested 88.1 [118] 81.7 [164] 79.4 [63] 0.054
95% CI (80.9, 93.4) (74.9, 87.3) (67.3, 88.5)
By type of ARV experience:
cART only 68.2 [22] 75.9 [54] 62.5%[24] 0.317
95% CI (45.1, 86.1) (62.4, 86.5) (40.6, 81.2)
Mono-dual NRTI 93.2 [88] 86.9 [99] 87.9 [33] 0.066
95% CI (85.8, 97.5) (78.6, 92.8) (71.8, 96.6)
TCE 94.5 [55] 88.3 [94] 93.8 [32] 0.426
95% CI (84.9, 98.9) (80.0, 94.0) (79.2, 99.2)
Part B. Frequency of class-speciﬁc mutations—among all patients tested in the year
NRTI resistance 82.2 [118] 73.8% [164] 66.7% [63] 0.096
95% CI (74.1, 88.6) (66.4, 80.3) (53.7, 78.0)
NNRTI resistance 46.6 [118] 65.2% [164] 55.6% [63] 0.165
95% CI (37.4, 56.0) (57.4, 72.5) (42.5, 68.1)
PI resistance 65.2 [118] 50.6% [164] 41.3% [63] 0.018
95% CI (55.9, 73.8) (42.7, 58.5) (29.0, 54.4)
Triple-class resistance 33.9 [118] 39.6% [164] 27.0% [63] 0.748
95% CI (25.4, 43.2) (32.1, 47.6) (16.6, 39.6)
Part C. Frequency of class-speciﬁc mutations—among tested with prior ARV exposures
NRTI resistance 82.2 [118] 73.8% [164] 66.7% [63] 0.094
95% CI (74.1, 88.6) (66.4, 80.3) (53.7, 78.0)
NNRTI resistance 70.5 [78] 75.8% [128] 68.1% [47] 0.384
95% CI (59.1, 80.3) (67.4, 82.9) (52.9, 80.9)
PI resistance 71.4 [105] 56.3% [144] 45.5% [55] 0.010
95% CI (61.8, 79.8) (47.7, 64.5) (32.0, 59.4)
Triple-class resistance 65.5 [55] 55.3% [94] 40.6% [32] 0.094
95% CI (51.4, 77.8) (44.7, 65.6) (23.7, 59.4)
∗Linear test for trend using annual estimates for entire period 1999–2008.
Numbers in square brackets indicate denominators (i.e., patients with eligible GT each year).
CI: conﬁdence interval. GT: genotypic testing; cART: combination antiretroviral therapy; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-
nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; TCE: triple-class exposed.
Although we did not detect statistically signiﬁcant
declines in the frequency of any ARV resistance among
HIV strains from all HOPS patients who underwent GT
in clinical practice and among the subset who were solely
cART-experienced, recent population-based studies provide
supporting evidence for such declines. These studies suggest
that the incidence of ARV resistance is decreasing [19, 20]
due to increasing use of cART regimens that are more
tolerable, potent, easier to adhere to, and consequently less
likely to result in resistance [18, 21, 22]a n dd u et os m a l l e r
proportions of patients failing antiretroviral therapy [7, 19]
or being suﬃciently viremic while receiving cART to allow
for the performance of GT.
We also found that HOPS patients who underwent GT
were increasingly less likely to have virus with PI resistance,
whereas potential declines in NNRTI resistance were more
modest and nonsigniﬁcant over time. These trends might
reﬂect shorter persistence of PI mutations than NNRTI
mutations in the absence of drug pressure or greater use
of ritonavir-boosted PIs, which are more potent and confer
greater barriers to the emergence of resistance. Among ARV-
na¨ ıve patients initiating cART who were followed in British
Columbia, Canada, the development of ARV drug resistance
was associated with the use of non-boosted PI-based or
NNRTI-based regimens [18], suboptimal levels of ARV
adherence (particularly in the 80%–95% range), low pre-
cART CD4+ cell counts, and high baseline HIV RNA levels
[18, 28], and was reduced for patients who initiated cART
in 2002–2004 versus earlier [18]. In the Swiss Cohort study,
the estimated prevalence of resistance in a population of over
8,000 ARV-exposed patients also decreased by approximately
12% during 1999 to 2007 and was driven by loss to follow8 AIDS Research and Treatment
up or death of patients with mono-dual NRTI exposure
counteredbycontinuedenrollmentofpatientsstartingcART
with NNRTI-based or boosted PI-based regimens [17].
We excluded from our primary analyses genotypic
tests performed on plasma HIV RNA samples with
≤1,000copies/mL because such assays may provide unreli-
able results (i.e., appear falsely negative for resistance muta-
tions) due to insuﬃcient HIV RNA copy and such patients
may have low level self-limited viremia (viral “blips”) rather
than true virologic failure. Indeed, when comparing results
from genotypic tests performed when HIV RNA >1,000
copies/mL versus ≤1,000 copies/mL in the latest years of
the study, we found that the frequency of “insuﬃcient
specimens” was higher, while the frequency of detected
resistance was lower in the latter group, especially when HIV
RNA <500 copies/mL. Aside from concern for bias due to
nonevaluable samples, including the relatively few results
from genotypic tests performed with HIV RNA between
500 and 1,000copies/mL would have likely accentuated
the observed decreases in the frequencies of resistance at
GT through 2008. Our analytic approach ensured more
comparable data over time, and the declines in resistance we
observed are likely conservative.
Our ﬁndings suggestive of declines over time in rates
of ARV resistance are notable for at least two reasons.
First, because of the method we employed to analyze
cumulative frequency of ARV resistance to date, by “carrying
forward” previously identiﬁed mutations that may have
become archived, the frequency of resistance in later years
should tend to be higher (because patients have had the
opportunity to accumulate more mutations over time as
revealedbysuccessivegenotypictestsperformed)thanwould
be suggested if results were based on a single genotypic
test that year. Further, one might expect to ﬁnd higher
overall frequency of mutations over time, as newer ARVs
are added to the three drug classes, with new, often ARV-
speciﬁc, resistance mutations being identiﬁed and detected
using contemporary genotypic tests.
Webelievethatthreefactorsmostlikelyexplain thelower
frequency of resistance among HOPS patients who under-
went GT over time: (i) the increasing use of more tolerable
and potent cART regimens associated with higher barriers to
resistance or more complex mutational pathways necessary
for resistance to develop; (ii) the decreasing proportion
of HOPS patients under observation having mono-dual
NRTI exposure; (iii) the increasing and more widespread
use of GT in the HOPS with possible testing of patients
at lower risk of virologic failure due to resistance. The
decreasing frequency of resistance to PIs in our population
was associated with increased use of more potent PIs (i.e.,
ritonavir boosting). This trend could have also occurred if
exposures to PIs were increasingly distant, which would have
allowed greater opportunity for PI resistance mutations to
becomearchivedbeforepatientsunderwentGT.However,we
found no evidence that the time between PI exposure among
exposed patients and time of genotypic test diﬀered over the
study observation period.
In a cohort study of 1,587 HIV-infected patients at the
University of North Carolina (2000–2006), of whom 607 had
at least one genotype, there were 27.2% of patients with
TCR among 437 patients who had GT and any exposure
to each of the three drug classes. This was lower than the
40.6% estimated for patients with TCE in our study, possibly
becausewerequiredaminimumofthreemonthsofexposure
on each of the three drug classes to deﬁne TCE [25]. Our
ﬁndings of high frequency of any resistance mutations in the
genotyped population are consistent with the ﬁndings from
an early large genotypic substudy of patients with HIV viral
load >500 copies/mL in the population-based HIV Cost and
Service Utilization Study (HCSUS), which documented that
76% of tested patients had evidence of genotypic resistance
to one or more antiretroviral drugs in 1996–1998 [23].
The ﬁndings from our ecological analyses should be
interpreted in light of several additional caveats and limi-
tations. First, most patients receiving antiretrovirals in the
HOPS were virologically suppressed and, over time, fewer
were eligible for GT during the study period, resulting in
a progressively smaller and more select sample of patients
with GT results, raising the concern for potential bias and
limiting statistical power. Second, we relied on data collected
in the course of regular HIV care since our purpose was to
reﬂect what a treating clinician would see. Not all eligible
patients had GT performed, and trends in and magnitude of
resistance frequencies detected may have been diﬀerent if all
ARV-experienced,viremicpatientshadundergonescheduled
GT at regular intervals [16]. Third, some mutations that
arose during prior courses of ARV therapy (before the
advent of GT or before HOPS entry) may have no longer
been apparent because of a lack of continuing ARV drug
pressure; however, we do not believe this eﬀect would have
systematically biased our ﬁndings over calendar years away
from the null hypothesis. Fourth, patients who harbored
the greatest number of mutations were also more likely
to have had advanced HIV disease and an extensive ARV
treatment history that involved mono-dual NRTI exposure
(data not shown). These patients may have died or been lost
to follow up at rates higher than other HOPS patients during
the study period. Moreover, the demographics of patients
who underwent GT shifted toward a higher percentage of
women, persons of color, and those with heterosexual risk
for HIV infection, all factors which are associated with more
recent HIV diagnoses and less exposure to ART in the HOPS
(data not shown). These dynamics may explain in part the
decreasing trends in resistance in our open cohort. Finally,
we have no systematic data on pre-ARV resistance proﬁles
for the majority of patients and therefore could not evaluate
the role of primary transmitted drug resistance or incidence
rates of HIV resistance.
Inconclusion,thefrequencyofARVresistancemutations
detected for HIV among patients in the HOPS who were
tested in the course of routine clinical practice was high
and tended to decrease during 1999–2008. The decreasing
frequency of genotypic resistance corresponded with at least
two trends: an increasing use of more tolerable and potent
cART, including boosted PI regimens, and a decreasing
proportion of HOPS patients with histories of exposure toAIDS Research and Treatment 9
mono- and dual-NRTI ARV regimens. Our ﬁndings support
the continuing need for routine HIV resistance testing and
monitoringofevolvingARVresistancepatternsamongARV-
treated patients [15] who experience virologic nonsuppres-
sion while on therapy. Available evidence suggests that
adoption of such testing as routine would facilitate tailoring
of more eﬀective cART [29], reduce the likelihood of further
resistance evolution, and ultimately augment cART-related
reductions in HIV-related mortality [7, 8, 12].
Appendix
The HIVOutpatientStudy (HOPS)
Investigators,2011
The HOPS Investigators currently include the following
investigatorsandsites:John T.Brooks,KateBuchacz,Marcus
Durham,DivisionofHIV/AIDSPrevention,NationalCenter
for HIV, STD, and TB Prevention (NCHSTP), Centers for
Disease Control and Prevention (CDC), Atlanta, GA; Kath-
leen C. Wood, Rose K. Baker, James T. Richardson, Darlene
Hankerson, and Carl Armon, Cerner Corporation, Vienna,
VA; Frank J. Palella, Joan S. Chmiel, Carolyn Studney, and
Onyinye Enyia, Feinberg School of Medicine, Northwestern
University, Chicago, IL; Kenneth A. Lichtenstein and Cheryl
Stewart, National Jewish Medical and Research Center
Denver, CO; John Hammer, Benjamin Young, Kenneth S.
Greenberg, Barbara Widick, and Joslyn D. Axinn, Rose Med-
ical Center, Denver, CO; Bienvenido G. Yangco and Kalliope
Halkias, Infectious Disease Research Institute, Tampa, FL;
Douglas J. Ward and Jay Miller, Dupont Circle Physicians
Group, Washington, DC; Jack Fuhrer, Linda Ording-Bauer,
Rita Kelly, and Jane Esteves, State University of New York
(SUNY), Stony Brook, NY; Ellen M. Tedaldi, Ramona A.
Christian, Faye Ruley and Dania Beadle, Temple University
School of Medicine, Philadelphia, PA; Richard M. Novak and
Andrea Wendrow, University of Illinois at Chicago, Chicago,
IL.
Abbreviations
NNRTI: non-nucleoside reverse transcriptase
inhibitor
PI: protease inhibitor
PIB: ritonavir-boosted protease inhibitor
NRTI: nucleoside reverse transcriptase inhibitor
TCE: triple-class exposed.
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